The biotech industry has made significant progress in treating and preventing HIV, but a true cure remains elusive. Recent developments in gene editing and synthetic antibodies have sparked hope for a breakthrough. Companies like AELIX Therapeutics and Excision BioTherapeutics are working on innovative therapies, including CRISPR-based treatments and therapeutic vaccines. These advancements could reshape the HIV landscape and bring us closer to a cure.
Forecast for 6 months: Expect further clinical trials and data releases from AELIX Therapeutics and Excision BioTherapeutics, providing more insight into the efficacy and safety of their treatments.
Forecast for 1 year: Gilead Sciences’ acquisition of AELIX Therapeutics’ HTI vaccine assets will likely accelerate the development of a therapeutic vaccine, potentially leading to a significant reduction in treatment fatigue and viral reservoirs.
Forecast for 5 years: CRISPR-based therapies, such as Excision BioTherapeutics’ EBT-101, may become a standard treatment option for HIV, offering a potential cure for millions of people worldwide.
Forecast for 10 years: The HIV landscape will be transformed by the widespread adoption of gene editing technologies, leading to a significant reduction in new infections and a near-elimination of the virus.
